Back to Authors

Wheless, James W.

https://orcid.org/0000-0002-4735-3431

Mayo Clinic

University of Tennessee Health Science Center

Citations 29

Burden of Seizure Clusters on Patients with Epilepsy and Caregivers (P6.343)
Sirven, Joseph I , Penovich, Patricia , Buelow, Janice M. , Wheless, James W.

Neurology | December 7, 2023 | Volume: 86 | Issue: 16_supplement | Pages: No page available

10.1212/wnl.86.16_supplement.p6.343 Get It

The Patient-Clinician Relationship in Seizure Cluster Management (P1.069)
Penovich, Patricia , Sirven, Joseph I , Buelow, Janice M. , Wheless, James W.

Neurology | December 7, 2023 | Volume: 86 | Issue: 16_supplement | Pages: No page available

10.1212/wnl.86.16_supplement.p1.069 Get It

Evaluation of Diazepam Nasal Spray in Patients with Epilepsy Concomitantly Using Maintenance Benzodiazepines: Interim Analysis from a Phase 3, Long-term, Open-label Safety Study (1760)
Segal, Eric , Miller, Ian , Dlugos, Dennis , Biton, Victor, Cascino, Gregory, Desai, Jay , Liow, Kore , Cook, David F. , Tarquinio, Daniel Charles , Wheless, James W. , Hogan, R Edward , Sperling, Michael R. , Rabinowicz, Adrián L. , Carrazana, Enrique

Neurology | December 7, 2023 | Volume: 96 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.96.15_supplement.1760 Get It

Time to Second Doses in Emergency Seizure Patients Treated With Valtoco® (diazepam nasal spray) Across 24 Hours: Subgroup Results From a Completed Phase 3, Open-label, Repeat Dose Safety Study (1756)
Liow, Kore , Segal, Eric , Miller, Ian , Desai, Jay , Dlugos, Dennis , Biton, Victor, Cascino, Gregory, Wheless, James W. , Sperling, Michael R. , Hogan, R Edward , Tarquinio, Daniel Charles , Rabinowicz, Adrián L. , Carrazana, Enrique

Neurology | December 7, 2023 | Volume: 96 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.96.15_supplement.1756 Get It

Safety Profile of Valtoco® (diazepam nasal spray) in Patients With Epilepsy: Final Results From a Phase 3, Open-Label, 12-Month Repeat Dose Safety Study (1753)
Liow, Kore , Segal, Eric , Miller, Ian , Desai, Jay , Dlugos, Dennis , Biton, Victor, Cascino, Gregory, Wheless, James W. , Sperling, Michael R. , Hogan, R Edward , Tarquinio, Daniel Charles , Carrazana, Enrique , Rabinowicz, Adrián L.

Neurology | December 7, 2023 | Volume: 96 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.96.15_supplement.1753 Get It

Effectiveness and Safety of Valtoco® (NRL-1; diazepam nasal spray) in Patients With Epilepsy and a History of Seasonal Allergies: Interim Results From a Phase 3, Open-Label, 12-Month Repeat Dose Study (2048)
Vázquez, Blanca , Liow, Kore , Segal, Eric , Miller, Ian , Mauney, Weldon, Desai, Jay , Dlugos, Dennis , Biton, Victor, Cascino, Gregory D. , Sperling, Michael R. , Wheless, James W. , Hogan, R Edward , Tarquinio, Daniel Charles , Ayala, Ricardo, Carrazana, Enrique , Rabinowicz, Adrián L.

Neurology | December 7, 2023 | Volume: 94 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.94.15_supplement.2048 Get It

Safety and Tolerability of NRL-1, an Intranasal Formulation of Diazepam, in Relationship to Usage Frequency in Subjects With Epilepsy: Interim Results From a Phase 3, Open-label, Repeat Dose Study (1992)
Miller, Ian , Dlugos, Dennis , Biton, Victor, Cascino, Gregory D. , Liow, Kore , Vázquez, Blanca , Segal, Eric , Mauney, Weldon, Desai, Jay , Wheless, James W. , Hogan, R Edward , Sperling, Michael R. , Ayala, Ricardo, Tarquinio, Daniel Charles , Carrazana, Enrique , Rabinowicz, Adrián L.

Neurology | December 7, 2023 | Volume: 94 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.94.15_supplement.1992 Get It

Timing to Administration and Ease of Dosing of Diazepam Nasal Spray Rescue Therapy for Seizure Clusters: Results From a Phase 3, Long-Term Open-Label, Repeat-Dose Safety Study (P15-8.001)
Desai, Jay , Liow, Kore , Dlugos, Dennis , Cascino, Gregory, Hogan, R Edward , Wheless, James W. , Sperling, Michael R. , Tarquinio, Daniel Charles , Misra, Sunita N. , Rabinowicz, Adrián L. , Carrazana, Enrique

Neurology | December 6, 2023 | Volume: 98 | Issue: 18_supplement | Pages: No page available

10.1212/wnl.98.18_supplement.1655 Get It

Safety of a Second Dose of Diazepam Nasal Spray Within 4 Hours in Patients With Seizure Clusters: Final Results From a Long-Term, Phase 3, Open-Label, Repeat-Dose Safety Study (P14-8.003)
Cascino, Gregory, Desai, Jay , Tarquinio, Daniel Charles , Wheless, James W. , Hogan, R Edward , Sperling, Michael R. , Liow, Kore , Misra, Sunita N. , Rabinowicz, Adrián L. , Carrazana, Enrique

Neurology | December 6, 2023 | Volume: 98 | Issue: 18_supplement | Pages: No page available

10.1212/wnl.98.18_supplement.1605 Get It

Severe communication delays are independent of seizure burden and persist despite contemporary treatments in SCN1A + Dravet syndrome: Insights from the ENVISION
Perry, Μ. Scott , Scheffer, Ingrid E. , Sullivan, Joseph , Brunklaus, Andreas , Boronat, Susana , Laux, Linda , Patel, Anup D. , Roberts, Colin, Dlugos, Dennis , Holder, Deborah , Lallas, Matt, Phillips, Steven , Segal, Eric , Smeyers, Patricia , Lal, Dennis , Brünger, Tobias , Wojnaroski, Mary , Maru, B., O'Donnell, Penrose, Morton, Magda F., James, Emma S. , Huang, Norman, Gofshteyn, Jacqueline S. , Rico, Salvador , Perry, Michael Scott , Patel, Anup D , Knupp, Kelly G , Lal, Dennis , Wirrell, Elaine C , Vila, Maria Candida , Gofshteyn, Jacqueline S , Rico, Salvador , Brunklaus, Andreas , Scheffer, Ingrid E , James, Emma S , Wheless, James W. , Knupp, Kelly G. , Wirrell, Elaine , Zuberi, Sameer M. , Huang, Norman

Epilepsia | December 4, 2023 | Volume: 65 | Issue: 2 | Pages: 322-337

10.1111/epi.17850 Get It

Abstract Objective Dravet syndrome (DS) is a developmental and epileptic encephalopathy characterized by high seizure burden, treatment‐resistant epilepsy, and developmental stagnation. Family members rate communication deficits among the most impactful disease manifestations. We evaluated seizure burden and language/communication development in children with DS. Methods ENVISION was a prospective, observational study evaluating children with DS associated with SCN1A pathogenic variants ( SCN1A + DS) enrolled at age ≤5 years. Seizure burden and antiseizure medications were assessed every 3 months and communication and language every 6 months with the Bayley Scales of Infant and Toddler Development 3rd edition and the parent‐reported Vineland Adaptive Behavior Scales 3rd edition. We report data from the first year of observation, including analyses stratified by age at Baseline: 0:6–2:0 years:months (Y:M; youngest), 2:1–3:6 Y:M (middle), and 3:7–5:0 Y:M (oldest). Results Between December 2020 and March 2023, 58 children with DS enrolled at 16 sites internationally. Median follow‐up was 17.5 months (range = .0–24.0), with 54 of 58 (93.1%) followed for at least 6 months and 51 of 58 (87.9%) for 12 months. Monthly countable seizure frequency (MCSF) increased with age (median [minimum–maximum] = 1.0 in the youngest [1.0–70.0] and middle [1.0–242.0] age groups and 4.5 [.0–2647.0] in the oldest age group), and remained high, despite use of currently approved antiseizure medications. Language/communication delays were observed early, and developmental stagnation occurred after age 2 years with both instruments. In predictive modeling, chronologic age was the only significant covariate of seizure frequency (effect size = .52, p = .024). MCSF, number of antiseizure medications, age at first seizure, and convulsive status epilepticus were not predictors of language/communication raw scores. Significance In infants and young children with SCN1A + DS, language/communication delay and stagnation were independent of seizure burden. Our findings emphasize that the optimal therapeutic window to prevent language/communication delay is before 3 years of age.